Nano-vesicles based on phospholipid-like amphiphilic polyphosphazenes to orally deliver ovalbumin antigen for evoking anti-tumor immune response
Source abstract
Abstract
Aimed at evoking an adequate anti-tumor immune response via oral administration route, this study constructed functionally and structurally mimicking-bacteria-membrane (MBM) nano-vesicle (RGD-PEOP) to orally deliver ovalbumin (OVA) antigen. In terms of simulating bacterial membrane structure, we creatively designed this nano-vesicle to have phospholipid-like octadecylphosphoethanolamine groups in vesicle membrane to improve OVA loading by means of specific interactions including salt bridge and hydrogen bond interaction. For simulating bacterial membrane function, the RGD peptide was modified onto the nano-vesicle surface, and the resulting vector displayed a good transport ability with a 3.4-fold higher than free OVA. In vitro and in vivo assay showed that the expression of co-stimulatory molecules and MHC class II complexes was significantly enhanced by MBM nano-vesicle. IFN-γ and IL-4 levels also increased several folds in the MBM nano-vesicle group. Consequently, MBM nano-vesicle achieved the highest in vivo inhibition rate of 69% against E.G7-OVA tumors among all the oral groups. These results suggest that this MBM nano-vesicle may be a promising vector to orally deliver OVA antigen for cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Developing an effective non-bacterial carrier for oral cancer immunotherapy remains challenging. This work constructed a mimicking-bacteria-membrane nano-vesicle based on phospholipid-like amphiphilic polyphosphazenes for oral delivery of ovalbumin antigen. With the considerable capability to load ovalbumin antigen and target M cells, the nano-vesicle produced remarkable tumor suppression in vivo by evoking anti-tumor immune response.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Driving CAR T-cells forward10.1038/nrclinonc.2016.36 ↗
2. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
3. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current cinical developments10.1038/mt.2009.5 ↗
4. Crossing the barrier: targeting epithelial receptors for enhanced oral vaccine delivery10.1016/j.jconrel.2012.02.006 ↗
5. Mucosal immune system and m cell-targeting strategies for oral mucosal vaccination10.4110/in.2012.12.5.165 ↗
6. Pharmacology and toxicology of an oral tablet whole cells inactivated cholera vaccine in Sprague Dawley rats10.1016/j.vaccine.2011.02.074 ↗
7. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein10.1007/s00262-017-1984-0 ↗
8. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy10.1021/acs.nanolett.5b00570 ↗
9. Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m
10. Advances in vaccine adjuvants10.1038/15058 ↗
11. Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates against cervical cancer10.1021/bm400626w ↗
12. Polymeric materials for gene delivery and DNA vaccination10.1002/adma.200801478 ↗
13. Recent trends in vaccine delivery systems: a review10.4103/2230-973X.82384 ↗
14. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells10.1016/j.addr.2012.10.005 ↗
15. Lectins and microparticles for enhanced oral vaccination10.1016/j.ymeth.2005.09.009 ↗
16. Sequentially dual-targeting vector with nano-in-micro structure for improved docetaxel oral delivery in vivo10.2217/nnm-2016-0259 ↗
17. Methylated N-(4-N,N-dimethylaminocinnamyl) chitosan-coated electrospray OVA-loaded microparticles for oral vaccination10.1016/j.ijpharm.2013.03.015 ↗
18. Fluorescence correlation spectroscopy for the study of membrane dynamics and protein/lipid interactions10.1016/j.ymeth.2008.06.011 ↗
19. X-ray crystallographic analysis of lipid-protein interactions in the bacteriorhodopsin purple membrane10.1146/annurev.biophys.32.110601.142516 ↗
20. Model systems, lipid rafts, and cell membranes1
21. Membrane lipids: where they are and how they behave10.1038/nrm2330 ↗
22. The role of lipids in defining membrane protein interactions: insights from mass spectrometry10.1016/j.tcb.2012.08.007 ↗
23. A small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation10.1074/jbc.M109.096214 ↗
24. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting10.1016/S1359-6446(05)03536-1 ↗
25. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan10.1016/j.biomaterials.2013.11.073 ↗
26. In vitro and in vivo models for the study of oral delivery of nanoparticles10.1016/j.addr.2013.01.003 ↗
27. The mucosal immune system in the oral cavity—an orchestra of T cell diversity10.1038/ijos.2014.48 ↗
28. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach10.1016/j.jconrel.2006.08.013 ↗
29. M-cell surface β1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer’s patch M cells10.1128/IAI.66.3.1237-1243.1998 ↗
30. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids10.1016/j.bmc.2005.08.048 ↗
31. Constructing aptamer anchored nanovesicles for enhanced tumor penetration and cellular uptake of water soluble chemotherapeutics10.1016/j.actbio.2016.02.012 ↗
32. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor10.1084/jem.176.6.1693 ↗
33. Phospholipid-cholesterol interaction. Kinetics of water permeability in liposomes10.1021/bi00775a029 ↗
34. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination10.1016/j.jconrel.2007.04.021 ↗
35. M-Cell surface β1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse peyer’s patch M cells10.1128/IAI.66.3.1237-1243.1998 ↗
36. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination10.1016/j.ejpb.2009.04.009 ↗
37. Polymeric materials for gene delivery and DNA vaccination10.1002/adma.200801478 ↗
38. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses10.1016/S1074-7613(03)00296-6 ↗
39. Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system10.1016/S0165-2478(03)00043-9 ↗
40. Poly [di (sodium carboxylatoethylphenoxy) phosphazene](PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens10.1016/j.vaccine.2006.10.011 ↗
41. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications
42. Chitosan/sulfated locust bean gum nanoparticles: in vitro and in vivo evaluation towards an application in oral immunization10.1016/j.ijbiomac.2016.12.076 ↗
43. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan10.1016/j.biomaterials.2013.11.073 ↗
44. Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG10.1016/j.biomaterials.2014.07.055 ↗
45. Regulation of interferon-γduring innate and adaptive immune responses10.1016/S0065-2776(07)96002-2 ↗
46. Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a10.4049/jimmunol.163.8.4175 ↗